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Abstract
Background: Melphalan has been used in the treatment of various hematologic malignancies for almost 60 years.
Today it is part of standard therapy for multiple myeloma and also as part of myeloablative regimens in association with
autologous allogenic stem cell transplantation. Melflufen (melphalan flufenamide ethyl ester, previously called J1) is an
optimized derivative of melphalan providing targeted delivery of active metabolites to cells expressing aminopeptidases.
The activity of melflufen has compared favorably with that of melphalan in a series of in vitro and in vivo experiments
performed preferentially on different solid tumor models and multiple myeloma. Melflufen is currently being evaluated
in a clinical phase I/II trial in relapsed or relapsed and refractory multiple myeloma.
Methods: Cytotoxicity of melflufen was assayed in lymphoma cell lines and in primary tumor cells with the Fluorometric
Microculture Cytotoxicity Assay and cell cycle analyses was performed in two of the cell lines. Melflufen was
also investigated in a xenograft model with subcutaneous lymphoma cells inoculated in mice.
Results: Melflufen showed activity with cytotoxic IC50-values in the submicromolar range (0.011-0.92 μM) in
the cell lines, corresponding to a mean of 49-fold superiority (p < 0.001) in potency vs. melphalan. In the primary
cultures melflufen yielded slightly lower IC50-values (2.7 nM to 0.55 μM) and an increased ratio vs. melphalan (range
13–455, average 108, p < 0.001). Treated cell lines exhibited a clear accumulation in the G2/M-phase of the cell cycle.
Melflufen also showed significant activity and no, or minimal side effects in the xenografted animals.
Conclusion: This study confirms previous reports of a targeting related potency superiority of melflufen compared to
that of melphalan. Melflufen was active in cell lines and primary cultures of lymphoma cells, as well as in a xenograft
model in mice and appears to be a candidate for further evaluation in the treatment of this group of malignant diseases.
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Background
In their pioneering work on nitrogen mustards, Gilman
and Philips [1] laid the foundation for modern cancer
chemotherapy. These compounds were chemically unstable
to hydrolysis and efforts were soon made to increase the
stability without reduction of activity. Substitution with
electron-withdrawing groups, e.g., a substituted phenyl ring,
decreased the rate of aziridinium ion formation and reactiv-
ity of the nitrogen mustard [2]. In the early fifties the British
scientists Bergel and Stock hypothesized that certain
natural amino acids or peptides might, when modified by
appropriate groups, show anti-tumor activity by interfer-
ence with the nucleic acid or protein metabolism of malig-
nant cells [3]. In this work the D, L, and DL-form of p-
bis(2-chloroethyl)aminophenylalanine were synthesized and
high activity of the L-form, but only slight activity of the D-
form, was demonstrated in a Walker rat carcinoma model
[4, 5]. The lead compound was later named “melphalan”,
the name being derived from mustard-L-phenylalanine [6].
Intravenous melphalan has single-agent activity in a variety
of human malignancies including for example breast
cancer, ovarian cancer, testicular cancer and multiple
myeloma [7–9]. It was also acknowledged early on, that
in poor-prognosis patients with lymphoma, multiple mye-
loma, or neuroblastoma, high-dose melphalan-containing
regimens (>140 mg/m2) yielded both high response rates
and improved survival, despite considerable toxicity [10].
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Melphalan is an important component in the high-dose
conditioning chemotherapy regimen most used for
lymphoms, BEAM (BCNU, etoposide, cytarabine and
melphalan).
Malignant lymphomas are a group of tumors originating
from cells of the lymphatic system. The lymphomas are
classified according to the WHO-classification into B-cell
lymphomas, T-cell lymphomas and Hodgkin lymphoma
(HL) and further into many different entities. Of the B-cell
lymphomas, diffuse large B-cell lymphoma (DLBCL) is the
most common subtype. Systemic chemotherapy is the
mainstay of therapy for all lymphomas and approximately
60–70 % of DLBCL patients are cured. In HL even higher
cure rates are possible, and the chemotherapy may be
combined with radiotherapy. Poor responders and/or early
relapse patients at young age and good physical condition
are often considered for high dose chemotherapy and
stem cell transplantation. Still a significant proportion of
lymphoma patients relapse, and there is a need for new
drugs to further improve the results and reduce the tox-
icity of treatment [11, 12].
Melflufen (L-melphalanyl-p-L-fluorophenylalanine ethyl
ester hydrochloride, previously called J1) is a derivative of
the classical alkylating agent melphalan. Chemically mel-
flufen may be described as the ethyl ester of a dipeptide
consisting of melphalan and para-fluoro-L-phenylalanine.
The drug is susceptible to hydrolysis by aminopeptidases,
like aminopeptidase N (APN; also designated CD13) for
which melflufen is a substrate [13], that are frequently
expressed or overexpressed in tumor tissue [14], providing
the molecule with a target directed delivery to cells [15]. It
has been demonstrated that melflufen exposure to various
malignant cells in vitro results in at least a 10–20 fold
higher intracellular concentration of melphalan in com-
parison with direct treatment with equimolar doses of
melphalan [13, 15, 16]. The result is a cytotoxic IC50-value
of melflufen significantly lower than for melphalan (10-
600-fold lower in various in vitro cell systems) [15, 17, 18].
The advantage of melflufen vs. melphalan has also been
demonstrated in various hollow fiber and/or xenograft hu-
man tumor models in rodents [16, 19, 20].
Increased expression of various hydrolytic enzymes like
peptidases, esterases and proteases has been described in
several types of human malignancies, especially those char-
acterized by fast-growing and aggressive phenotypes [21].
Among these enzymes the metalloproteinase APN has
received substantial attention as a marker and mediator of
the malignant phenotype, as well as a possible target for
anticancerous chemotherapy [14]. It has recently been
shown that APN is directly involved in targeted delivery of
melflufen resulting in intracellular enrichment of melpha-
lan and subsequent cell death [16, 22]. APN is commonly
expressed in hematopoietic malignancies of myelomonocy-
tic origin and has less commonly been described in
lymphoid neoplasms. However, expression of APN has
been described in anaplastic large cell lymphoma [23, 24].
In addition, the aminopeptidase inhibitor bestatin (Ubeni-
mex) inhibits the proliferation of histiocytic lymphoma cell
line U937 and induces morphological, cytochemical and
functional differentiation into monocyte/macrophages [25].
Bestatin has also been evaluated in clinical trials showing
therapeutic efficacy and survival benefit in diseases like
acute myeloid leukemia (AML) and lymphomas [26].
This study was undertaken to characterize the activity
of melflufen against lymphoma cells in vitro and in vivo.
Methods
Cell lines & cell culture
Cytotoxicity was assayed in a panel of twelve human
lymphoma cell lines. A brief description of the cell lines is
presented in Table 1. The identity of the cell lines was con-
firmed by department of Laboratory Medicine, Karolinska
Institutet in collaboration with department of Oncology
and Pathology, Cancer Center Karolinska, Karolinska
Institutet, Stockholm, Sweden.
All lymphoma and CCRF-CEM cells were cultured in
RPMI 1640 cell growth medium (Sigma-Aldrich, St Louis,
MO, USA) supplemented with 10–20 % heat-inactivated
fetal calf serum, 2 mM glutamine, 100 U/mL penicillin,
and 100 μg/mL streptomycin (all chemicals from Sigma
Aldrich). Cells were grown at 37 °C in a humidified atmos-
phere containing 5 % carbon dioxide, split twice weekly
and harvested in log-phase for experimental use.
Patient tumor cells from 16 patients with different lymph-
oma subtypes were also analyzed for in vitro sensitivity
(Table 2). The samples were obtained by routine surgery,
diagnostic biopsy or bone marrow/peripheral blood sam-
pling. The use of patient samples was approved by the re-
gional Ethics Committee of Uppsala University (Ns 2008/
246 and 2014/233). Informed consent was waived. Lymph-
oma cells were isolated from bone marrow or peripheral
blood by 1.007 g/ml Ficoll-Paque (Pharmacia Biotech, Upp-
sala) density gradient centrifugation [27]. Tumor tissue from
solid samples was minced into small pieces and tumor cells
were then isolated by collagenase dispersion followed by
purification on Percoll (Kabi Pharmacia) or Ficoll density
gradient centrifugation [28]. Cell viability was determined by
trypan blue exclusion test and the proportion of tumor cells
in the preparation was judged by inspection of May–Grun-
wald–Giemsa-stained cytospin preparations by a cytopathol-
ogist. Cell culture medium RPMI 1640 (supplemented as
described above) was used throughout. In some cases, cells
were cryopreserved in a medium containing 10 % dimethyl-
sulfoxide (DMSO, Sigma-Aldrich) and 90 % inactivated
calf serum by initial freezing for 24 h at −70 °C, followed by
storage at −150 °C. Cryopreservation in this way does not
affect drug sensitivity [29]. The characteristics of the primary
cultures of human lymphoma cells are listed in Table 1.
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Drugs and chemicals
Melphalan (Fig. 1a) was obtained as Alkeran® from the
Swedish Pharmacy (Apoteket AB, Sweden), or bought as
a pure chemical from Sigma Aldrich. Melflufen (Fig. 1b,
kind gift from Oncopeptides AB, Stockholm, Sweden)
was dissolved in DMSO and further diluted in sterile water
or phosphate buffered saline (PBS; Sigma-Aldrich). All dilu-
tions with water were made immediately prior to the start
of the experiments to minimize the influence of mustard
hydrolysis. The standard drugs vincristine, doxorubicin,
etoposide, and cytarabine (all from Sigma), as well as 4-
hydroxy-cyclophosphamide (4-HC, the active metabolite of
cyclophosphamide, purchased from Niomech – IIT GmbH,
Bielefeld, Germany) were dissolved in DMSO and diluted
in PBS or sterile water prior to start of the experiments.
The fluorometric microculture cytotoxicity assay FMCA
Cell viability after drug exposure (cytotoxic efficacy) was
analyzed with the fluorometric microculture cytotoxicity
assay (FMCA) which has been described in detail previ-
ously [30, 31]. The FMCA is a total cell kill assay per-
formed in 96- or 384-well microtiterplates, and based on
measurement of fluorescence generated from hydrolysis
of fluorescein diacetate (FDA; Sigma-Aldrich). Cell lines
were harvested in log-phase and seeded (45 μL/well)
into 384-well microtiter plates (Nunc) at a concentration
of 100,000 cells/ml using pipetting robot Biomek® 2000
(Beckman Coulter). The plates were incubated at 37 °C
in humidified atmosphere containing 95 % air and 5 %
CO2 for 24 h followed by the addition of drugs (2.5 nl
portions/well of DMSO drug stock) using Echo 550
Liquid Handler (Labcyte). The plates were further incu-
bated for 72 h. Patient lymphoma cells were handled
similarly or seeded (45 μL/well, 40,000 cells/well) into
drug containing (5 μL/well) 384-well microtiter plates.
The plates were incubated at 37 °C, in humidified at-
mosphere containing 95 % air and 5 % CO2 for 72 h.
Each drug concentration was tested in duplicates. Each
384-well microtiter plate had three columns without
drugs serving as controls, and one column with medium
served as blank. The cells were subsequently washed
with PBS and supernatant aspirated leaving 10 μl in each
well, before the addition of 50 μL, 10 μg/mL FDA. Plates
were incubated for 60 min before measurement of fluores-
cence (485/538 nm for excitation and emission respect-
ively) in a Fluostar Omega. The fluorescence generated is
proportional to the number of cells in the well with an in-
tact plasma membrane, and data are presented as Survival
Table 1 List of cell lines used in the study
Cell line ID Cell type Subtype Resource Reference Authentication Y/N
DB ACC539 DLBCL GCB DSMZ, Braunschweig, Germany [34, 35] Y
DOHH-2 ACC47 DLBCL GCB DSMZ, Braunschweig, Germany [36] N
HDLM-2 ACC 17 HL GCB DSMZ, Braunschweig, Germany [37, 38] N
KM-H2 ACC 8 HL GCB DSMZ, Braunschweig, Germany [37, 39] N
L-428 ACC 197 HL GCB DSMZ, Braunschweig, Germany [37, 40] N
OCI-LY3 ACC 761 DLBCL ABC DSMZ, Braunschweig, Germany [41, 42] Y
RC-K8 ACC561 DLBCL ABC DSMZ, Braunschweig, Germany [41, 43] Y
SU-DHL-6 ACC572 DLBCL GCB DSMZ, Braunschweig, Germany [44, 45] Y
SU-DHL-10 ACC576 DLBCL GCB DSMZ, Braunschweig, Germany [44, 46] Y
U-2932 ACC633 DLBCL ABC DSMZ, Braunschweig, Germany [47, 48] Y
U-2940 ACC634 DLBCL PMBL DSMZ, Braunschweig, Germany [30] Y
WSU-NHL ACC58 DLBCL GCB DSMZ, Braunschweig, Germany [31, 34] N
Table 2 Characteristics of primary cells from lymphoma patients
Sample No. Diagnosis Status at analysis
1 Indolent lymphoma Refractory
2 Indolent lymphoma Refractory
3 MCL Refractory
4 NHL nos Refractory
5 T-LB Primary
6 DLBCL Refractory
7 NHL nos Refractory
8 FL Refractory
9 Lymphoma nos Primary




14 DLBCLtr GC Refractory
15 DLBCLtr GC Refractory
16 B-cell lymphoma nos Primary
MCL Mantle cell lymphoma, NHL Non-Hodgkin lymphoma, T-LB
Lymphoblastlymphoma of T-cell type, FL Follicular lymphoma, T-PLL
Prolymphocytic leukemia of T-cell type, DLBCLtr GC Diffuse large B-cell
lymphoma transformed from follicular lymphoma of germinal centre
subtype, Nos Not otherwise specified
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Index (SI %), defined as the mean fluorescence of the test
wells expressed as a percentage of control cultures, with
blank values subtracted.
Quality criteria for a successful assay included > 75 %
starting viability (judged by Trypan blue exclusion), a con-
trol signal more than ten times the blank, and finally, a co-
efficient of variation in control and blank wells of < 30 %.
Cell cycle distribution analysis
Cell cycle distribution analyses were performed on mel-
flufen treated (0.1, 0.2 and 0.4 μM) and control cells
from the KM-H2 and SU-DHL-10 cell lines in which the
cytotoxic activity of melflufen during the 72 h FMCA
assay was calculated as 0.92, 0.22, and 0.71 μM respect-
ively (see Table 3). To minimize potential artifacts eman-
ating from cells exiting the analyzed cell populations,
e.g. due to early and/or extensive cell death, the cells
were subjected to basal cell culture conditions for 40 h
(preincubation) followed by 12, 24 and 48 h treatments
with melflufen. Propidium iodide (PI) staining of DNA
using Vindelöv’s technique was followed by quantitation
with flow cytometry analysis. The percentage of cells in
each cell cycle phase was determined with the ModFit
LT software.
Effect of melflufen in DOHH-2 xenografted mice
The xenograft study was performed at Pipeline Biotech
A/S, Trige, Denmark and was approved by the national
authority “Danish Animal Experiments Inspectorate”
(2012-15-2934-00051 C1). The animals had FELASA
(Federation for Animal Science Laboratory Associations)
SPF-status and the housing and changing systems were
designed to assure that the SPF-status was preserved
during the study. Diet (Altromin 1324) and water was
administered ad libitum.
Fig. 1 Chemical structure of melflufen (a) and melphalan (b)
Table 3 Cytotoxic activity (as IC50 μM) of standard drugs and melflufen in the panel of cell lines
Drugs/Cell lines Vincristine Doxorubicin 4-HC Etoposide Cytarabine Bortezomib Melphalan Melflufen
DB 0.013 0.052 25 2.4 30 0.0020 44 0.92
DOHH-2 0.030 0.050 22 2.3 9.6 0.0063 17 0.39
HDLM-2 0.0023 0.15 16 3.9 0.83 0.0031 9.3 0.088
KM-H2 0.0025 0.034 5.7 0.65 >100 0.0024 8.6 0.22
L-428 0.14 0.089 24 2.0 31 0.0044 9.4 0.73
Ly-3 0.0026 0.044 0.77 0.24 1.4 0.0028 0.52 0.011
RC-K8 0.14 0.059 21 2.7 8.7 0.0071 12 0.45
SU-DHL-6 0.0014 0.053 6.7 2.7 7.0 0.0023 38 0.42
SU-DHL-10 0.00026 0.19 17 49 0.080 0.0047 29 0.71
U-2932 0.0037 0.18 17 3.5 0.84 0.0038 19 0.52
U-2940 0.020 0.026 1.6 0.34 0.91 0.0052 9.8 0.12
WSU-NHL 0.0015 0.032 3.8 1.5 0.17 0.0028 6.9 0.077
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Female C.B-17 Scid female mice (nomenclature: C.B-lgh-
1b Prkdcscid/lcrTac), 5–7 week of age at arrival, were sup-
plied from Taconic-Europe, Denmark, and after 7 days of
acclimatization inoculated subcutaneously with 5×106
DOHH-2 cells into the right flank. Appearance of tumors
was carefully monitored, and the tumors were scored (if
not large enough to be measured) or measured three times
a week. Tumor diameters were measured in two dimen-
sions using a digital caliper and the volume was estimated
by the following formula: L × W × ½ W (Length ×
Width × ½ Width). Measurements/observations began
at day 0, i.e. the day of inoculation. After randomization
on day 21 the animals were allocated to groups and
dosed with intravenously injected vehicle (2 mL/kg, three
times weekly, control group), vincristine (1 mg/kg, three
times weekly, positive control), or melflufen (3 mg/kg, two
times weekly, test group). Treatment continued for two
weeks, and mice were terminated by cervical dislocation
at the end of the experiments or at humane endpoints
(maximal tumor size, weight loss of > 20 %, wounds, etc).
Statistics
The cytotoxic IC50-vaules (inhibitory concentration 50 %)
for the drugs were determined from log concentration-
effect curves in Graph Pad Prism (GraphPad software
Inc., CA, USA) using non-linear regression analysis. Stat-
istical considerations and comparisos between melphalan
and melflufen groups were based on logIC50-values and
made with two-sided paired t-test, and for three groups
one-way ANOVA was used. For comparison between sur-
vival curves log-rank test was used. In all tests p < 0.05
was considered significant.
Results
Cytotoxic activity in lymphoma cell lines
The cytotoxic activity of melflufen in human lymphoma
cell lines is presented in Table 3. The calculated IC50-
values varied almost 100-fold among the cell lines, iden-
tifying the DLBCL cell lines Ly-3 as the most sensitive
cell line (IC50-values for melphalan and melflufen being
0.52 and 0.011 μM respectively) and DB as the most re-
sistant (44 and 0.92 μM). Melflufen was consistently more
potent than melphalan throughout the panel, and the
average ratio of IC50-values was 49-fold (range 12 to 102,
p < 0.001). The pattern of sensitivity among the cell lines
was similar for all standard chemotherapeutic drugs. As
expected, the correlation coefficients of log IC50-values
between the alkylating agents was high (Pearson’s correl-
ation = 0.83 for melflufen vs 4-HC, and =0.88 for melflu-
fen vs melphalan) in this panel of lymphoma cells.
Interestingly, bortezomib deviated from this pattern, and
all cell lines appeared sensitive to this drug with compar-
ably small variations in IC50 (range 2.0–7.1 nM).
Cytotoxic activity in primary cultures of human
lymphoma cells
Figure 2 shows the cytotoxicity of melflufen in primary
human lymphoma cells, plotted as dose response curves
with survival index (SI %) for each concentration tested.
Sensitivity towards melflufen varied considerably (>300
fold) and the IC50 range from 2.7 nM to 0.55 μM. The
efficacy of melflufen corresponded to a 13- to 455-fold
potency improvement (p < 0.001) compared to melpha-
lan (Table 4).
Effect of treatment with melflufen on cell cycle phase
distribution
The effect of treatment with melflufen on cell cycle
phase distribution in KM-H2 and SU-DHL-10 cell lines
was analyzed by flow cytometry and illustrates distribu-
tion of the cell cycle phases G0/G1, S and G2/M. After a
48 h treatment with melflufen, a clear accumulation of
cells in the G2/M phase was seen, and this response was
detected in both cell lines tested (Fig. 3). However it was
much more pronounced in SU-DHL-10 cell line. In SU-
DHL-10 cells, G2 arrest was already seen after 24 h of
treatment with melflufen. For KM-H2 cells, 48 h were
needed. In all tested concentrations a dramatic increase
in G2 after 48 h of treatment was seen which is consist-
ent with the cells trying to divide yet unable to do it due
to DNA damage and thus arresting in G2.
Activity in DOHH-2 xenografts
Melflufen significantly inhibited growth of the subcuta-
neously xenografted DOHH-2 lymphoma tumors during
the treatment period (Fig. 4a) and prolonged survival
(Fig. 4b) compared to the vehicle treated control. Prema-
ture sacrifice in the vehicle treated control group but














Fig. 2 Activity of melflufen in primary lymphoma cells. The cytotoxicity
of melflufen in human primary lymphoma cells, after incubation for 72
h, was tested by the Fluorometric Cytotoxicity Assay. Each dose
response curve is one patient cell culture, plotted as survival index (%)
as a function of concentration
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not in the melflufen group was done due to large tumors
(4 of 5 animals). All remaining animals were terminated
on day 37. Treatment with melflufen intravenously on a
twice-weekly schedule at the dose 3 mg/kg had no detect-
able effect on animal health or weight development during
the experiment, and all animals survived until termination.
In contrast, the positive control group (treated with
vincristine) presented significant body weight loss, and
two animals reached the toxicity endpoint (-20 % body
weight) at or before the end of the experiment (Fig. 4c).
Discussion
Melphalan has been used for almost sixty years in the
treatment of a broad spectrum of malignancies and is
part of many combinations regimes. Melphalan belongs
to a class of agents, i.e. alkylators, which exert cytotoxic
action through covalent interaction with intracellular
nucleophiles, especially DNA. Difunctional agents, able
to crosslink a DNA strand within a double helix (intras-
trand), between two strands (interstrand) or between DNA
and proteins, are usually more active than monofunctional
agents. Although covalent adduct formation is the mechan-
ism of cytotoxicity common to all the antitumor alkylating
agents, these drugs have widely different potency, toxicity
and disease selectivity. Differences in the non-alkylating
Table 4 IC50 (μM) for melphalan and melflufen, and melphalan/
melflufen ratio in primary human lymphoma cells
Patient no IC50 melphalan (μM) IC50 melflufen (μM) Ratio
1 1.7 0.018 94
2 6.7 0.51 13
3 7.0 0.059 118
4 19 0.053 363
5 89 0.55 162
6 8.5 0.12 73
7 29 0.11 271
8 6.0 0.018 337
9 2.8 <0.01 278
10 0.73 0.0080 91
11 13 0.079 160
12 1.2 0.0027 455
13 31 0.080 388
14 NA NA NA
15 24 0.90 27
16 16 0.66 24
MEAN 8.4 0.078 108
The potency difference between melphalan and melflufen was statistically
significant (p < 0.001, paired 2-tailed t–test)
Fig. 3 Effects of melflufen on cell cycle phase distribution. KM-H2 (a) and SU-DHL-10 (b) cell lines were incubated for 40 h during basal conditions
before treatment with melflufen for 12, 24 and 48 h. The analyses were performed by flow cytometry and show distribution of the cell cycle
phases G0/G1, S and G2/M resulting from treatment with melflufen 0.1-0.4 μM
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portions of these molecules probably lead to different bio-
distribution and normal tissue toxicity of these drugs [8].
New representatives of this class of drugs are continuously
introduced, such as temozolomide and bendamustin.
The clinical use of most chemotherapeutic agents is
limited by the associated toxicity, often originating from
organs with high proliferation (e.g. bone marrow). Many
attempts have been made to, more or less, specifically
target the tumor cells or the tumor microenvironment,
for example, the use of a prodrug approach where the
prodrug is selectively activated in tumors overexpressing
the prodrug-activating enzyme(s) [32]. Many such targets
have been suggested in the literature, among them different
aminopeptidases like APN, which is described as overex-
pressed in many malignant tissues making it a possible and
attractive target for cancer chemotherapy [14]. Melflufen is
a dipeptide derivative carrying melphalan as one of its
amino acid moieties. Compelling evidence shows that the
activity benefit of melflufen compared to melphalan
originates from APN dependent intracellular cleavage
of melflufen yielding high concentrations of melphalan
in the cytoplasm, i.e. a targeted delivery [14, 16, 22].
APN/CD13 is commonly expressed in hematopoietic ma-
lignancies of myelomonocytic origin and has less com-
monly been described in lymphoid neoplasms. However,
effects of the aminopeptidase inhibitor bestatin on lymph-
oma cells have been shown in vitro [26], and the effects of
this drug in lymphoma patients have also been evaluated in
clinical trials [26, 33]. Wickstrom et al. [18] investigated the
effects of melflufen in primary cultures of tumor cells from
176 patients with various diagnoses. Among these were
fourteen patients with lymphoma, and the in vitro activity
difference between melphalan and melflufen was in this
diagnosis exceptionally high (160×) prompting further in-
vestigation of the activity of melflufen in lymphoma.
The results presented here show that melflufen is in-
deed an active drug both in Hodgkin and non-Hodgkin
lymphoma cell lines in vitro, yielding IC50-values in the
range of 11 nM to 0.92 μM. A similar pattern was found
in patient cells (IC50 of 2.7 nM to 0.55 μM) clearly sug-
gesting that lymphoma is a possible clinical diagnosis for
future use of melflufen. The in vivo xenograft model
study indicated modest activity of melflufen in the dose
and regimen used (3 mg/kg on a twice weekly schedule),
but on the other hand, without any signs of toxicity the
dose and/or intensity of the treatment schedule could
most probably be increased. Animals in the positive con-
trol group suffered severely from toxicity, and albeit excel-
lent tumor control, some of them had to be prematurely
sacrificed due to treatment associated weight loss.
Conclusion
The conclusion of this study demonstrates that melflufen
is an active drug against lymphoma in vitro and in vivo
and further evaluation in this diagnosis seems warranted.
Ethics approval and consent to participate
The xenograft study was performed at Pipeline Biotech
A/S, Trige, Denmark and was approved by the national
authority “Danish Animal Experiments Inspectorate”
(2012-15-2934-00051 C1).
The use of patient samples was approved by the regional
Ethics Committee of Uppsala University (Ns 2008/246 and
2014/233).
The use of the patients’ samples in research was ap-
proved without written informed consent of the patients.
The reasons why the ethical committee waived informed
consent were that the patients had approved storing of
samples in the Uppsala biobank and that these samples
could be used for research after ethical approval without
contacting the patient if the committee found the re-
search of good quality and not compromising integrity
of the patient. Furthermore, all patients included in this
Fig. 4 Effects of melflufen in subcutaneous DOHH-2 xenografted mice. Presented as tumor volume (a), survival (b) and body weight change (c).
Mice in control group (n = 5) gained weight and showed no signs of toxicity, but individuals were prematurely sacrificed due to tumor size
on day 33 (n = 2) and 35 (n = 2). Animals in vincristine control group had excellent tumor control but lost weight and one animal was
sacrificed on day 25, one on day 33 due to >20 % weight reduction. Animals treated with melflufen had no weight loss but significant
tumor growth reduction on day 33 (p < 0.05). Log-rank test showed a significant difference in survival between the control group and the
melflufen treated group (p = 0.0144). In A and C mean values with SEM are displayed
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study have given an oral informed consent but that was
not a requirement of the ethical committee.
Availability of data and materials
The datasets supporting the conclusions of this article
are included within the article.
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